Targovax initiates clinical immunotherapy trial to treat RAS-mutated cancer
20 April 2017 | By Niamh Marriott, Junior Editor
Targovax has recruited the first patient in an exploratory Phase Ib clinical trial of TG02 in patients with locally recurrent RAS-mutated rectal cancer...